Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-DOTATATE PET/CT in Pediatric Neuroendocrine Tumors
NCT04040088Phase 1Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2019
- Primary completion
- Jul 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gallium ga 68 dotatate in neuroblastoma, ganglioneuroblastoma (GNB) and ganglioneuroma (2 cohorts), sponsored by Mayo Clinic. Primary endpoint: Difference in radiation treatment target volume definition between 68Ga-DOTATATE PET/CT and iobenguane (MIBG) up to 3 months. Started Sep 2019; status: active, not recruiting.
02
Drugs
gallium ga 68 dotatate
03
Conditions
neuroblastomaganglioneuroblastoma (GNB)ganglioneuroma
Beyond the preview
Go deeper on NCT04040088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04040088.